Market Closed -
Nasdaq
04:00:00 2024-05-22 pm EDT
|
5-day change
|
1st Jan Change
|
0.6998
USD
|
+0.94%
|
|
+9.34%
|
+36.47%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
891.9
|
1,626
|
1,393
|
311.2
|
52.27
|
84.27
|
-
|
-
|
Enterprise Value (EV)
1 |
632.8
|
1,125
|
1,022
|
68.24
|
0.3947
|
65.04
|
-3.872
|
30.67
|
P/E ratio
|
-2.9
x
|
-4.73
x
|
-4.34
x
|
-1.46
x
|
-0.2
x
|
-1.06
x
|
-0.87
x
|
-0.94
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
286%
|
286%
|
286%
|
Capitalization / Revenue
|
-
|
-
|
68.5
x
|
4.9
x
|
6.1
x
|
0.73
x
|
1.07
x
|
0.89
x
|
EV / Revenue
|
-
|
-
|
50.3
x
|
1.07
x
|
0.05
x
|
0.57
x
|
-0.05
x
|
0.33
x
|
EV / EBITDA
|
-2.19
x
|
-3.74
x
|
-3.09
x
|
-0.25
x
|
-0
x
|
-0.96
x
|
-0.14
x
|
-0.33
x
|
EV / FCF
|
-2.62
x
|
-6.07
x
|
-4.42
x
|
-0.25
x
|
-0
x
|
-1.63
x
|
0.05
x
|
-0.77
x
|
FCF Yield
|
-38.1%
|
-16.5%
|
-22.6%
|
-402%
|
-49,198%
|
-61.5%
|
1,963%
|
-130%
|
Price to Book
|
3.22
x
|
3.14
x
|
5.28
x
|
2.64
x
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
54,151
|
82,816
|
88,417
|
94,879
|
101,922
|
120,416
|
-
|
-
|
Reference price
2 |
16.47
|
19.63
|
15.76
|
3.280
|
0.5128
|
0.6998
|
0.6998
|
0.6998
|
Announcement Date
|
2/27/20
|
3/1/21
|
2/28/22
|
2/8/23
|
3/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
20.34
|
63.57
|
8.573
|
114.7
|
78.73
|
94.26
|
EBITDA
1 |
-288.6
|
-300.7
|
-331.1
|
-274.9
|
-271.2
|
-67.76
|
28.33
|
-92.54
|
EBIT
1 |
-295.7
|
-309.1
|
-340.5
|
-280.5
|
-276
|
-81.29
|
-72.64
|
-93.23
|
Operating Margin
|
-
|
-
|
-1,673.85%
|
-441.25%
|
-3,219.48%
|
-70.89%
|
-92.27%
|
-98.91%
|
Earnings before Tax (EBT)
1 |
-291
|
-306.6
|
-340.1
|
-228.3
|
-276.1
|
-82.3
|
-90.25
|
-70.5
|
Net income
1 |
-291
|
-306.6
|
-340.1
|
-228.3
|
-276.1
|
-84.43
|
-105.7
|
-92.73
|
Net margin
|
-
|
-
|
-1,672.28%
|
-359.12%
|
-3,220.88%
|
-73.63%
|
-134.24%
|
-98.38%
|
EPS
2 |
-5.670
|
-4.150
|
-3.630
|
-2.240
|
-2.610
|
-0.6600
|
-0.8000
|
-0.7450
|
Free Cash Flow
1 |
-241.4
|
-185.3
|
-231.1
|
-274.6
|
-194.2
|
-40
|
-76
|
-40
|
FCF margin
|
-
|
-
|
-1,136.19%
|
-431.98%
|
-2,265.25%
|
-34.88%
|
-96.54%
|
-42.43%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
2.000
|
2.000
|
2.000
|
Announcement Date
|
2/27/20
|
3/1/21
|
2/28/22
|
2/8/23
|
3/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
7.548
|
7.314
|
51.58
|
4.459
|
0.221
|
1.226
|
0.957
|
2.138
|
4.252
|
27.36
|
32.21
|
24.89
|
30.04
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-93.4
|
-88.22
|
-32.13
|
-84.62
|
-75.54
|
-75.02
|
-71.41
|
-69.61
|
-59.96
|
-31.25
|
-16.53
|
-20.49
|
-13.05
|
Operating Margin
|
-1,237.45%
|
-1,206.18%
|
-62.3%
|
-1,897.78%
|
-34,180.54%
|
-6,118.92%
|
-7,462.28%
|
-3,255.94%
|
-1,410.21%
|
-114.22%
|
-51.3%
|
-82.33%
|
-43.43%
|
Earnings before Tax (EBT)
1 |
-93.32
|
-88.1
|
18.47
|
-84.08
|
-74.57
|
-74.75
|
-71.11
|
-69.82
|
-60.44
|
-31.73
|
-14.8
|
-31.3
|
-4.55
|
Net income
1 |
-93.35
|
-88.1
|
18.47
|
-84.09
|
-74.57
|
-74.77
|
-71.11
|
-69.8
|
-60.45
|
-31.75
|
-13.4
|
-24.99
|
-14.42
|
Net margin
|
-1,236.74%
|
-1,204.61%
|
35.8%
|
-1,885.87%
|
-33,742.99%
|
-6,098.78%
|
-7,430.3%
|
-3,264.59%
|
-1,421.68%
|
-116.07%
|
-41.61%
|
-100.4%
|
-48.01%
|
EPS
2 |
-0.9600
|
-0.8700
|
0.1800
|
-0.8200
|
-0.7200
|
-0.7200
|
-0.6800
|
-0.6600
|
-0.5600
|
-0.2300
|
-0.1033
|
-0.1867
|
-0.1333
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/28/22
|
5/5/22
|
8/8/22
|
11/8/22
|
2/8/23
|
5/8/23
|
8/8/23
|
11/1/23
|
3/28/24
|
5/9/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
259
|
501
|
371
|
243
|
51.9
|
19.2
|
88.1
|
53.6
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-241
|
-185
|
-231
|
-275
|
-194
|
-40
|
-76
|
-40
|
ROE (net income / shareholders' equity)
|
-92.4%
|
-81.4%
|
-91.7%
|
-54.1%
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-79.2%
|
-65.9%
|
-64.4%
|
-112%
|
-
|
-
|
-
|
-
|
Assets
1 |
367.4
|
465.6
|
528.1
|
203.1
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
5.120
|
6.250
|
2.990
|
1.240
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
5.73
|
4.51
|
10.6
|
4.19
|
1.22
|
0.4
|
8
|
10
|
Capex / Sales
|
-
|
-
|
52.02%
|
6.6%
|
14.27%
|
0.35%
|
10.16%
|
10.61%
|
Announcement Date
|
2/27/20
|
3/1/21
|
2/28/22
|
2/8/23
|
3/28/24
|
-
|
-
|
-
|
Last Close Price
0.6998
USD Average target price
4.175
USD Spread / Average Target +496.60% Consensus |
1st Jan change
|
Capi.
|
---|
| +36.47% | 84.27M | | +9.99% | 115B | | +12.01% | 106B | | -3.07% | 24.69B | | -1.11% | 21.97B | | -5.29% | 19.27B | | -6.90% | 17.56B | | -39.36% | 17.32B | | +5.82% | 14.03B | | +33.05% | 12.13B |
Bio Therapeutic Drugs
|